Braveheart Bio (NASDAQ:BRVE) Hits New 52-Week Low - Here's What Happened

Key Points

• Braveheart Bio shares fell 7.1% to a new 52-week low of $24.31, closing at $25.50 compared with the prior close of $27.44.
• Five research firms initiated coverage with positive ratings, including several “Buy” recommendations; the stock has a consensus “Buy” rating and an average price target of $45.25.
• Insiders have shown strong buying activity, with purchases totaling 8.75 million shares worth approximately $157.5 million over the past 90 days, including major shareholder and director purchases at $18 per share.

Braveheart Bio, Inc. (NASDAQ:BRVE - Get Free Report) hit a new 52-week low on Tuesday . The company traded as low as $24.31 and last traded at $25.50, with a volume of 806205 shares traded. The stock had previously closed at $27.44.

Analysts Set New Price Targets

A number of research firms have recently issued reports on BRVE. Jefferies Financial Group assumed coverage on Braveheart Bio in a research report on Monday. They issued a "buy" rating and a $48.00 price objective for the company. The Goldman Sachs Group assumed coverage on Braveheart Bio in a report on Monday. They set a "buy" rating and a $48.00 target price on the stock. Cantor Fitzgerald assumed coverage on Braveheart Bio in a research note on Monday. They issued an "overweight" rating and a $40.00 price target on the stock. Stifel Nicolaus assumed coverage on Braveheart Bio in a report on Monday. They set a "buy" rating and a $45.00 price target for the company. Finally, TD Cowen began coverage on shares of Braveheart Bio in a report on Monday. They issued a "buy" rating on the stock. Five equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average target price of $45.25.

Braveheart Bio Stock Down 7.1%

Insider Buying and Selling

In related news, major shareholder Bio Fund Iv L.P. Ah purchased 1,100,000 shares of the company's stock in a transaction that occurred on Friday, August 7th. The stock was acquired at an average price of $18.00 per share, with a total value of $19,800,000.00. Following the completion of the purchase, the insider directly owned 10,232,420 shares in the company, valued at $184,183,560. This trade represents a 12.05% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Christopher Viehbacher purchased 83,333 shares of the business's stock in a transaction dated Friday, August 7th. The shares were purchased at an average cost of $18.00 per share, with a total value of $1,499,994.00. Following the acquisition, the director owned 609,519 shares in the company, valued at $10,971,342. This trade represents a 15.84% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders have purchased 8,751,942 shares of company stock valued at $157,534,956 in the last ninety days.

About Braveheart Bio

We are a clinical‑stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (“HCM”) and other serious cardiovascular diseases. Our lead product candidate, BHB‑1893, is a next-generation oral small‑molecule cardiac myosin inhibitor (“CMI”), that we are developing for the treatment of obstructive HCM (“oHCM”) and non‑obstructive HCM (“nHCM”). Our goal is to improve the treatment options for these patients by enhancing speed of onset, depth of gradient response, systolic safety, and reversibility, and reducing prescribing complexity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source